Search clinical trials for: Chelating Agents

Total 186929 results

Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients

Aplastic Anemia

Russian Federation
Novartis Pharmaceuticals

Completed

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Iron Overload | Myelodysplastic Syndrome

United States, Canada
Mt. Sinai Medical Center, Miami

Completed

Chelation Therapy in Diabetic Patients With Critical Limb Ischemia (TACT-PAD)

Peripheral Arterial Disease | Critical Limb Ischemia

United States
Elliott Vichinsky

Completed

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Iron Overload | Thalassemia

United States
Assistance Publique - Hôpitaux de Paris

Completed

Iron-Chelating Therapy and Friedreich Ataxia

Friedreich Ataxia

France
Case Western Reserve University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone

Hematologic Diseases | Iron Overload | Hemoglobinopathies | Thalassemia | Beta-Thalassemia | Anemia (Iron-Loading)
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Safety, Tolerability, and Efficacy of Deferasirox in MDS

Myelodysplastic Syndromes | Hemosiderosis

Italy
Novartis Pharmaceuticals

Completed

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Anemia

United States
Novartis Pharmaceuticals

Completed

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

Transfusional Iron Overload in β-thalassemia

United States, Greece, Argentina, Germany, Belgium, Italy, United Kingdom, France, Tunisia, Canada, Turkey, Brazil
Chang Gung Memorial Hospital

Completed

Environmental Exposure to Lead and Progressive Renal Insufficiency in Type II Diabetic Nephropathy

Diabetic Nephropathies | Diabetes Mellitus, Type II

China
Novartis Pharmaceuticals

Completed

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

Myelodysplastic Syndromes | Fanconi Syndrome | Anemia, Aplastic | Beta-thalassemia | Anemia, Diamond-Blackfan

United States
Novartis Pharmaceuticals

Withdrawn

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
Novartis Pharmaceuticals

Completed

Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.

Hepatic Impairment

Germany
Novartis Pharmaceuticals

Terminated

Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study (MACS1574)

Myelodysplastic Syndrome | Transfusional Iron Overload

Spain, France, Italy, South Africa
Novartis

Completed

A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis

Beta-Thalassemia | Hemosiderosis

Egypt, Lebanon, Oman, Saudi Arabia, Syrian Arab Republic
Novartis Pharmaceuticals

Completed

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Myelodysplastic Syndrome | Thalassemia

Russian Federation
Ain Shams University

Unknown

An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients

Beta Thalassemia Major

Egypt
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study

Liver Iron Overload

Italy
Novartis Pharmaceuticals

Completed

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis (MIMAS)

Iron Overload

United Kingdom, Italy, Oman, United Arab Emirates, Lebanon, Thailand, Egypt
Kermanshah University of Medical Sciences

Unknown

Application of Desferal to Treat COVID-19

COVID-19

Iran, Islamic Republic of
Novartis Pharmaceuticals

Completed

Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

Chronic Iron Overload

Austria, Italy, Greece
Novartis Pharmaceuticals

Withdrawn

Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia (CENTAurus)

Thalassemia (Transfusion Delendent)
HaEmek Medical Center, Israel

Completed

Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox

Iron Overload | Thalassemia

Israel
Novartis Pharmaceuticals

Completed

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

Transfusional Iron Overload

Italy
Wolfson Medical Center
Hadassah Medical Organization; Tel-Aviv Sourasky Medical Center; Sheba Medical... and other collaborators

Completed

Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load

Myelodysplastic Syndrome

Israel
Novartis Pharmaceuticals

Completed

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Transfusional Iron Overload | β-thalassemia

Italy
University Hospital, Lille
ApoPharma

Completed

Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients (SAFEFAIRALS)

ALS (Amyotrophic Lateral Sclerosis) | Iron Overload

France
Novartis Pharmaceuticals

Completed

A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity

Transfusional Iron Overload

United States, Greece, Italy
University of Texas Southwestern Medical Center
Novartis Pharmaceuticals

Completed

Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

Porphyria Cutanea Tarda

United States
Novartis Pharmaceuticals

Completed

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) (ESCALATOR)

Iron Overload | Hemosiderosis | Beta-thalassemia Major | Rare Anemia

Egypt, Oman, Saudi Arabia, Syrian Arab Republic, Lebanon
Novartis Pharmaceuticals

Completed

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

Anemia | Hemosiderosis

United States, Germany, Belgium, United Kingdom, Italy, Canada, France
University Hospital, Grenoble
Novartis

Recruiting

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents (LODEFI)

Myelodysplasia

France
Novartis Pharmaceuticals

Completed

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Transfusional Hemosiderosis

United States
Novartis Pharmaceuticals

Completed

A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload

Transfusion-dependent Iron Overload

Egypt, Greece, Hong Kong, Taiwan, Germany, United Kingdom, Belgium, Italy, Spain, France, Israel, Korea, Republic of, Turkey, China, Australia, Denmark, Austria, Switzerland, Netherlands, South Africa, Lebanon, Malaysia, Thailand
Novartis Pharmaceuticals

Withdrawn

An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old (MACS2163)

β-thalassemia Major
Novartis Pharmaceuticals

Completed

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Transfusional Iron Overload | β-thalassemia Major | Pediatric Rare Anemia

Italy, France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

Iron Overload

Germany
Novartis Pharmaceuticals

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

Sickle Cell Disease

United States, Italy, United Kingdom, France, Canada
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Iron Overload | Hereditary Hemochromatosis

United States, Germany, Italy, Australia, Canada, France
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Terminated

Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

Myelodysplastic Syndromes

Italy
Assistance Publique - Hôpitaux de Paris
Association pour l'Etude des Fonctions Digestives (AEFD)

Unknown

Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda

Porphyria Cutanea Tarda

France
Masonic Cancer Center, University of Minnesota

Terminated

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Breast Cancer | Iron Overload | Ovarian Cancer | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Tanta University

Unknown

Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major (Al-hijamah)

AL-Hijama in Thalassmia Major

Egypt
Novartis Pharmaceuticals

Completed

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Myelodysplastic Syndromes | Beta-Thalassemia

Hungary
Novartis Pharmaceuticals

Completed

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

Beta Thalassemia Transfusion Dependent

Italy
Children's Hospital of Philadelphia
ApoPharma

Approved for marketing

Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

Iron Overload

United States
Memorial Sloan Kettering Cancer Center
Center for Experimental Therapeutics; F.M. KIRBY FOUNDATION

Recruiting

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Leptomeningeal Metastases

United States
Brigham and Women's Hospital
Massachusetts General Hospital; National Institute of Diabetes and Digestive... and other collaborators

Recruiting

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury (DEFEAT-AKI)

Acute Kidney Injury

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis

Transfusional Hemosiderosis | Chronic Anemia

Japan, Turkey, Spain, Poland, Singapore
CorMedix

Withdrawn

Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent

Acute Kidney Injury

Search clinical trials for: Chelating Agents

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations